At this year's ObesityWeek, GLP-1s aren’t the only talk of the town
SAN ANTONIO — As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted more than...
View ArticleBiotech industry worries over potential for RFK Jr. ally as FDA pick
US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential Trump administration is...
View ArticleMacroGenics pauses development of ADC; Cellectis deprioritizes CAR-T
Plus, news about Tango Therapeutics, Endo, Neurogene and Century Therapeutics: MacroGenics stopped dosing patients in ADC trial: After three patient deaths in a Phase 2 prostate cancer drug trial for...
View ArticleCVS names Aetna head, plans more pharmacy closures as new CEO takes over
In his first quarter leading CVS Health, CEO David Joyner laid out the initial steps he’s taking to rightsize the company, as challenges continue to plague its insurance business. As part of those...
View ArticleStudies show how once-obscure DNA circles drive cancer, and maybe even how to...
Scientists have unveiled a strategy for targeting a vulnerability in tiny circles of floating DNA that can drive aggressive cancers. These circles — known as extrachromosomal DNA, or ecDNA, because...
View ArticleQ&A: GSK’s CEO Emma Walmsley on the new Trump administration, trust, AI and...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley believes her company can work “constructively” with the incoming...
View ArticleCalifornia voters say yes to restrictions around 340B spending
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug discount program. According to unofficial results, 51.5% of voters said yes to...
View Article